Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Precigen, Inc. (PGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.22-16.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.64 → 0.62 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for PGEN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve cash flow break-even by end of 2026 | Precigen aims to reach cash flow break-even by end of 2026. | Improving | cash flow remains negative through FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
PGEN is a high-risk commercial growth and development story, not yet a profitable compounder. The long-term thesis is intact, supported by recent strong financial performance and growing product adoption, but confidence is medium and the business remains loss-making.
The valuation model indicates PGEN trades at a premium to peers, with optionality as the main reason for the gap. Model confidence is low, and the evidence does not show that the market has priced in the full combination of expensive valuation, weak fundamentals, and turbulence.
Near term, PAPZIMEOS revenue and patient access are progressing, while management continues to target cash flow break-even by the end of 2026. Cash and investments fell from $56.7 million in the first quarter to $38.7 million in the second, so reaching that goal depends on sales funding operations; the company also faces elevated risk and a 53% estimated chance of missing the next print.
The multi-year view hinges on continued PAPZIMEOS adoption and whether its sales can fund operations through the stated break-even goal. Near term, a guidance cut would be a meaningful negative, while continued strong results and higher guidance from healthcare sector leaders could support the sector backdrop. Progress in PRGN-2009 trials is another factor, though the evidence gives no new financial metrics for the program.
Over the next 1 to 3 years, the thesis rests on converting commercial growth into cash flow while managing clinical and execution risk. Recent performance supports the case, but losses and a premium valuation leave little room for weak delivery. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Precigen, Inc.'s published investment case. The stated target is EPS >= 0 by 2027-12-31. |
| Improving |
| EPS remains negative beyond FY27 |
Diluted EPS: $0.08 per share FY2026-Q3; GAAP. Published target: EPS >= 0 by 2027-12-31. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20260.08 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Successful product launches supported by FDA approvals | Recent FDA approval supports product launch and revenue growth. | Intact | loss of FDA approval or failure to launch key products | FDA approval secured; Q3 topline beat FDA approval in June 2026 and Q3 2026 earnings beat reinforce commercial adoption and regulatory success. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth from $124M in 2026 to $229M in 2027 | A primary condition in Precigen, Inc.'s published investment case. The stated target is revenue >= $229M by 2027-12-31. | Improving | revenue falls below $124M in FY26 or fails to grow toward $229M in FY27 | Revenue: $74.148M FY2026-Q3; GAAP. Published target: revenue >= $229M by 2027-12-31. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 202674,148,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.20 → $0.62 · observed estimates
$0.23B → $0.44B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.20 | $228,955,265 | 2 / 2 |
| 2026-07-25 | $0.20 | $229,022,000 | 3 / 3 |
| 2026-07-26 | $0.20 | $229,022,000 | 3 / 3 |
| 2026-07-27 | $0.20 | $229,022,000 | 3 / 3 |
| 2026-07-28 | $0.20 | $229,022,000 | 3 / 3 |
| 2026-07-29 | $0.20 | $229,022,000 | 3 / 3 |
| 2026-07-30 | $0.20 | $228,955,265 | 2 / 2 |
| 2026-07-31 | $0.20 | $229,022,000 | 3 / 3 |
| 2026-08-01 | $0.20 | $228,955,265 | 2 / 2 |
| 2026-08-02 | $0.20 | $229,022,000 | 3 / 3 |
| 2026-08-03 | $0.20 | $228,955,265 | 2 / 2 |
| 2026-08-04 | $0.20 | $228,955,265 | 2 / 2 |
| 2026-08-05 | $0.20 | $228,955,265 | 2 / 2 |
| 2026-08-06 | $0.20 | $228,955,265 | 2 / 2 |
| 2026-08-07 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-08 | $0.36 | $454,378,390 | 2 / 3 |
| 2026-08-09 | $0.36 | $454,378,390 | 2 / 3 |
| 2026-08-10 | $0.36 | $454,378,390 | 2 / 3 |
| 2026-08-12 | $0.68 | $454,378,390 | 3 / 3 |
| 2026-08-13 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-14 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-15 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-16 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-17 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-18 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-19 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-20 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-21 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-22 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-23 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-24 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-25 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-26 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-27 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-28 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-29 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-30 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-08-31 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-01 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-02 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-03 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-04 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-05 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-06 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-07 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-08 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-09 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-10 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-11 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-12 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-13 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-14 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-15 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-16 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-17 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-18 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-19 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-20 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-21 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-22 | $0.68 | $454,384,667 | 2 / 2 |
| 2026-09-23 | $0.68 | $454,384,633 | 2 / 2 |
| 2026-09-24 | $0.68 | $454,384,633 | 2 / 2 |
| 2026-09-25 | $0.68 | $454,384,633 | 2 / 2 |
| 2026-09-26 | $0.64 | $443,538,475 | 2 / 2 |
| 2026-09-27 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-09-28 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-09-29 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-09-30 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-01 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-02 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-03 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-04 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-05 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-06 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-07 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-08 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-09 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-10 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-11 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-12 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-13 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-14 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-15 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-16 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-17 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-18 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-19 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-20 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-21 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-22 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-23 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-24 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-25 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-26 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-27 | $0.64 | $443,538,475 | 3 / 3 |
| 2026-10-28 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-10-29 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-10-30 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-10-31 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-11-01 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-11-02 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-11-03 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-11-04 | $0.62 | $437,088,475 | 3 / 3 |
| 2026-11-05 | $0.62 | $437,088,475 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.